Robbins Arroyo LLP: Impax Laboratories, Inc. (IPXL) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & HAYWARD, Calif.--()--Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Impax Laboratories, Inc. (NASDAQGS: IPXL) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Impax securities between February 25, 2014 and November 3, 2016, for alleged violations of the Securities Exchange Act of 1934 by Impax's officers and directors. Impax, a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products.

View this information on the law firm's Shareholder Rights Blog:
www.robbinsarroyo.com/shareholders-rights-blog/impax-laboratories-inc-nov-2016

Impax Accused of Violating Antitrust Laws

According to the complaint, Impax submitted several filings with the U.S. Securities and Exchange Commission, attesting to the accuracy of financial reporting, the disclosure of any material changes to the company's internal control over financial reporting, and the disclosure of all fraud. In its filings, Impax noted that the principal competitive factors in the generic pharmaceutical market are: price, product quality, and the ability to identify and market niche products, among other things. The complaint alleges that Impax officials failed to disclose that: (1) Impax had engaged in conduct that would cause the antitrust division of the Department of Justice ("DOJ") and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (2) Impax received two subpoenas which sought documents relating to violations of the federal and state antitrust laws; (3) the DOJ investigation was likely to result in criminal charges against Impax for collusion of generic drug pricing; and (4) Impax lacked effective internal controls over financial reporting.

On November 3, 2016, Bloomberg published an article which discussed the DOJ's investigation about suspected price collusion by several pharmaceutical companies, including Impax. The article stated that "it's against the law for competitors to agree to set prices or coordinate on discounts, production quotas or fees that affect prices" and that charges could extend to high-level Impax executives. On this news, Impax's stock fell $4.00 per share, or over 19.5%, to close at $16.50 per share on November 3, 2016.

Impax Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Robbins Arroyo LLP
Darnell R. Donahue
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Release Summary

Do you own shares of Impax Laboratories Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Impax.

$Cashtags

Contacts

Robbins Arroyo LLP
Darnell R. Donahue
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com